Myelodysplastic syndromes (MDS) are treated based on type and risk assessment, but traditional therapies may not work for everyone. Clinical trials offer a way to explore emerging treatments and ...

Successful Management of Neutropenic Sepsis Is Key to Better Survival of Patients With Blood Cancer in Sri Lanka: Real-World Data From the Resource-Limited Setting Myelodysplastic syndromes (MDS) ...

More and more hematology factors and parameters can be analyzed with advanced equipment to better pinpoint which patients might have myelodysplastic syndromes (MDS)—but the differences in leading ...

Infection is the leading cause of death in LR-MDS patients, responsible for 24.6% of deaths within a year of diagnosis. Key risk factors for infection include intermediate or higher IPSS-R risk, ...

MPNs involve overproduction of blood cells, while MDS results in poorly formed cells, affecting blood cell function and counts. Diagnosis requires blood tests, bone marrow biopsy, and genetic testing ...

Racial and Ethnic Disparities in Receipt of Guideline-Concordant Pancreatic Cancer Care Among Older Adults in the United States Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases ...

Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results published in Blood Neoplasia. The ...

The treatment landscape for high-risk myelodysplastic syndromes (HR MDS) is evolving, moving from supportive care toward a ...

It's called myelodysplastic syndrome, or MDS. It's a blood and bone marrow disease, linked to the cancer treatment that once saved her life. The 51-year-old broke the news on Monday morning's show ...

SAN DIEGO and TORONTO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly ...